Shares of Scholar Rock SRRK rose 14% on Tuesday after the company announced the resubmission of a regulatory filing to the FDA, seeking approval for its investigational muscle-targeted therapy, apitegromab, to treat spinal muscular atrophy (SMA) in children and adults.
The company expects the agency to accept this filing within 30 days, and a review period of up to six months from the resubmission date. If accepted, SRRK anticipates a final decision in September 2026.
Scholar Rock had initially submitted this filing last year, which was granted priority review. The FDA issued a complete response letter (CRL) to the BLA in September, citing observations at Catalent’s Indiana fill-finish facility, owned by pharma giant Novo Nordisk. This CRL was not related to concerns around apitegromab’s efficacy or safety, suggesting that the core clinical profile remains intact.
Since then, Scholar Rock has worked with the FDA and the Catalent site to address the deficiencies. The resubmitted filing includes a second U.S.-based fill-finish facility, which should help strengthen supply chain reliability and support future commercial demand.
Both the original and resubmitted filings are supported by data from a pivotal late-stage study, which showed that treatment with apitegromab achieved statistically significant and clinically meaningful improvements in motor function in SMA patients. A similar filing is under review in the EU, with a final decision expected in mid-2026.
If approved, Scholar Rock’s apitegromab will compete with large pharmaceutical companies. This includes Biogen’s BIIB injectable drug Spinraza, Novartis’ NVS gene therapy Zolgensma and Roche’s RHHBY oral drug Evrysdi. These treatments currently dominate the SMA market and have generated blockbuster sales, highlighting the significant commercial opportunity in this space.
SRRK Stock Performance
Shares of Scholar Rock rose in response to the above announcement, as investors welcomed the resolution of prior regulatory hurdles and the renewed path toward potential approval.
The company currently has no approved or marketed products. If apitegromab secures FDA approval, it would mark the company’s first commercial product, enabling it to generate a recurring revenue stream. The potential launch would represent a key inflection point, transforming SRRK from a clinical-stage biotech into a commercial-stage company.
Year to date, the stock has risen nearly 12% compared with the industry‘s 4% growth.
Image Source: Zacks Investment Research
More on SRRK’s Apitegromab
Apitegromab is a fully human monoclonal antibody designed to inhibit the activation of myostatin, a protein primarily produced in skeletal muscle cells that acts as a negative regulator of muscle growth. By blocking myostatin signaling, the therapy aims to improve muscle strength and function in patients with neuromuscular disorders.
Apart from SMA, Scholar Rock is currently evaluating apitegromab for the treatment of people with a rare neuromuscular disease called facioscapulohumeral muscular dystrophy (FSHD). It expects to start a mid-stage study on the drug in this indication later this year.
Scholar Rock Holding Corporation Price
Scholar Rock Holding Corporation price | Scholar Rock Holding Corporation Quote
SRRK’s Zacks Rank
Scholar Rock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Novartis AG (NVS): Free Stock Analysis Report
Biogen Inc. (BIIB): Free Stock Analysis Report
Roche Holding AG (RHHBY): Free Stock Analysis Report
Scholar Rock Holding Corporation (SRRK): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).